NAI for Sepsis With Persistent Lymphopenia
Trial details
- Registry ID
- NCT07578558
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as ANKTIVA; N-803; Nogapendekin alfa-inbakicept
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| NAI for Sepsis With Persistent LymphopeniaNCT07578558 | IBRX | Phase 2 | Withdrawn | 2027-08-03Estimated |
| NAI Plus Standard of Care Compared To SOC Alone Plus Standard of Care in Critically Ill Adults With SepsisNCT07783789 | IBRX | Phase 2 | Not yet recruiting | 2028-05-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |